Overview
This study aims to collect convalescent plasma and use it as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.
Description
This study aims to use convalescent plasma as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit. Donors must have anti-SARS CoV2 antibodies. Recipients must be critically ill Covid-19 patients on mechanical ventilation.
Eligibility
Inclusion Criteria:
- Age: 18 years or more.
- Patient with Covid-19 confirmed with nuclear acid testing
- Critically ill patients with Covid-19 on mechanical ventilation. Potencially critically ill patients (with acute respiratory distress syndrome, septic shock and/or multiple organ failure) with Covid-19.
- Diagnosed with acute respiratory distress syndrome.
- Informed consent.
Exclusion Criteria:
- No consent.
- Symptoms for a period longer than 20 days.
- Not detectable by acid nuclear testing within 48 hours prior to elegibility.
- Descompensated congestive heart failure, in which receiving 500ml of intrasvascular volume signifies a life risk.
- History of severe adverse events or anaphylaxis to plasma components